Findings from negative urothelial carcinoma trial suggest ‘chemotherapy backbone matters’

SAN FRANCISCO — The addition of atezolizumab to platinum-based chemotherapy failed to significantly improve survival for patients with metastatic urothelial carcinoma, according to a final analysis of the randomized phase 3 IMvigor130 trial.
The findings — presented at ASCO Genitourinary Cancers Symposium — showed a trend toward improved OS with atezolizumab (Tecentriq, Genentech) but the difference did not cross the prespecified efficacy boundary.
The results prompted atezolizumab’s manufacturer last year to voluntarily withdraw the agent’s indication in the U.S.

SAN FRANCISCO — The addition of atezolizumab to platinum-based chemotherapy failed to significantly improve survival for patients with metastatic urothelial carcinoma, according to a final analysis of the randomized phase 3 IMvigor130 trial.
The findings — presented at ASCO Genitourinary Cancers Symposium — showed a trend toward improved OS with atezolizumab (Tecentriq, Genentech) but the difference did not cross the prespecified efficacy boundary.
The results prompted atezolizumab’s manufacturer last year to voluntarily withdraw the agent’s indication in the U.S.